What is the bioavailability of Ramelteon?
Which of the following is not a prodrug?
Which of the following local anesthetics exhibits significant extrahepatic metabolism?
Which kinetic process is responsible for the elimination of a large number of drugs?
Tricyclic antidepressants can alter the oral absorption of many drugs by which of the following mechanisms?
Blockade of nerve conduction by a local anesthetic is characterized by which of the following?
What is the rate of drug elimination?
High first-pass metabolism is characteristic of which of the following drugs?
In which quadrant of the buttock are intramuscular injections typically administered?
Sildenafil acts by blocking which enzyme?
Explanation: **Explanation:** **Ramelteon** is a selective melatonin receptor agonist (acting on $MT_1$ and $MT_2$ receptors) used primarily for the treatment of insomnia characterized by difficulty with sleep onset. **1. Why 2% is Correct:** Ramelteon is rapidly absorbed from the gastrointestinal tract after oral administration. However, it undergoes **extensive first-pass metabolism** in the liver, primarily mediated by the CYP1A2 isoenzyme. This high extraction ratio results in a very low systemic **bioavailability of less than 2%**. Despite this low bioavailability, its major active metabolite (M-II) circulates at much higher concentrations and contributes significantly to its therapeutic effect. **2. Why Incorrect Options are Wrong:** * **7% and 10%:** These values are too high for Ramelteon. While many drugs have low bioavailability (e.g., Morphine ~25-30%), Ramelteon is an extreme example of first-pass metabolism. * **30%:** This is a common bioavailability for drugs like Propranolol or Morphine, but it does not reflect the significant hepatic clearance seen with Ramelteon. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Agonist at $MT_1$ (regulates sleepiness) and $MT_2$ (regulates circadian rhythm) receptors in the suprachiasmatic nucleus. * **Drug Interactions:** Because it is metabolized by **CYP1A2**, it is strictly contraindicated with **Fluvoxamine** (a potent CYP1A2 inhibitor), which can increase Ramelteon levels by over 50-fold. * **Safety Profile:** Unlike benzodiazepines, Ramelteon has **no abuse potential**, is not a controlled substance, and does not cause rebound insomnia or withdrawal symptoms. * **Indication:** Specifically approved for **sleep-onset insomnia** (not sleep maintenance).
Explanation: **Explanation:** A **prodrug** is a pharmacologically inactive compound that must undergo metabolic conversion (usually in the liver) to become an active metabolite. **Diazepam** is the correct answer because it is an **active drug** itself. While it is metabolized into active metabolites like nordiazepam and oxazepam (contributing to its long duration of action), the parent compound possesses intrinsic therapeutic activity. **Analysis of Options:** * **Enalapril:** Most ACE inhibitors (except Captopril and Lisinopril) are prodrugs. Enalapril is converted by hepatic esterases into its active form, **Enalaprilat**. * **Sulindac:** This is a sulfoxide NSAID. It is inactive until metabolized into a **sulfide** derivative, which inhibits COX enzymes. This prodrug nature helps reduce direct gastric mucosal irritation. * **Cortisone:** This is a biologically inactive glucocorticoid. It must be converted into **Hydrocortisone (Cortisol)** by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in the liver to be effective. **High-Yield NEET-PG Pearls:** 1. **Mnemonic for Prodrugs:** "**A**ll **P**harmacists **S**hould **C**an **D**eliver **E**very **M**edicine **I**n **L**iquid **S**tate" (**A**CEIs except Capto/Lisinopril, **P**roton Pump Inhibitors, **S**ulindac/Sulfasalazine, **C**yclophosphamide, **D**opa/Dipivefrine, **E**nalapril, **M**ercaptopurine, **I**rinotecan, **L**evodopa, **S**tatin/Spironolactone). 2. **Exceptions:** Captopril and Lisinopril are the only two ACE inhibitors that are **not** prodrugs. 3. **Clinical Significance:** Prodrugs may have poor efficacy in patients with severe liver disease due to impaired metabolic activation.
Explanation: **Explanation:** Local anesthetics (LAs) are classified into esters and amides. While esters are metabolized by plasma pseudocholinesterases, **amides** are primarily metabolized by hepatic microsomal enzymes (CYP450). **Why Prilocaine is correct:** Prilocaine is an amide local anesthetic that is unique because it undergoes significant **extrahepatic metabolism**. While it is metabolized in the liver, a substantial portion is also metabolized in the **kidneys and lungs**. A specific metabolite of prilocaine, **o-toluidine**, is clinically significant as it can oxidize hemoglobin to methemoglobin, leading to **methemoglobinemia** (a high-yield side effect). **Why the other options are incorrect:** * **Lignocaine (Lidocaine):** The prototype amide LA. It is almost exclusively metabolized in the liver via oxidative dealkylation. It has a rapid onset but lacks significant extrahepatic clearance. * **Bupivacaine:** A long-acting amide LA. It is metabolized strictly by the liver. It is notably more cardiotoxic than other LAs due to its slow dissociation from cardiac sodium channels. * **Ropivacaine:** An S-enantiomer of bupivacaine with a similar metabolic profile (purely hepatic). It is preferred over bupivacaine for its reduced cardiotoxicity and greater sensory-motor dissociation. **High-Yield NEET-PG Pearls:** 1. **Methemoglobinemia:** Associated with **Prilocaine** and **Benzocaine**. The treatment of choice is **Methylene Blue**. 2. **Shortest acting Amide:** Lidocaine. 3. **Longest acting Amide:** Bupivacaine/Ropivacaine. 4. **Rule of Thumb:** Amide LAs have two "i"s in their name (L**i**doca**i**ne, Pr**i**loca**i**ne), while esters have only one (Proca**i**ne).
Explanation: ### Explanation **Correct Answer: A. First order** **Why it is correct:** Most drugs (approximately 95%) follow **First-order kinetics**. In this process, a **constant fraction** of the drug is eliminated per unit of time. This occurs because the elimination systems (enzymes and transporters) are not saturated; they have a high capacity relative to the drug concentration. Consequently, the rate of elimination is directly proportional to the plasma concentration. A key characteristic of first-order kinetics is that the **half-life ($t_{1/2}$) remains constant**, regardless of the dose administered. **Why the other options are incorrect:** * **Option D (Zero order):** Only a few drugs follow zero-order kinetics (e.g., Ethanol, high-dose Aspirin, Phenytoin). Here, a **constant amount** of drug is eliminated per unit of time because the elimination pathways are saturated. * **Option B & C (Mixed order/Michaelis-Menten kinetics):** These describe drugs that shift from one order to another. Specifically, **Phenytoin** exhibits zero-order kinetics at high therapeutic doses (saturation) and shifts to first-order kinetics as plasma levels fall below the saturation point. This is often referred to as "Capacity-limited elimination." **High-Yield Clinical Pearls for NEET-PG:** * **First Order:** Constant **fraction** eliminated; $t_{1/2}$ is constant; Rate $\propto$ Concentration. * **Zero Order:** Constant **amount** eliminated; $t_{1/2}$ is variable (increases with dose); Rate is independent of concentration. * **Mnemonic for Zero Order Drugs (WATT P):** **W**arfarin (at toxic doses), **A**lcohol/Aspirin, **T**heophylline, **T**olbutamide, **P**henytoin. * **Steady State:** For drugs following first-order kinetics, it takes approximately **4 to 5 half-lives** to reach a steady-state concentration.
Explanation: **Explanation:** **Mechanism of Action (Correct Answer):** Tricyclic antidepressants (TCAs), such as Amitriptyline and Imipramine, possess significant **antimuscarinic (anticholinergic) properties**. By blocking muscarinic receptors in the gastrointestinal tract, they decrease parasympathetic stimulation, leading to **delayed gastric emptying and reduced intestinal motility**. Since the rate of drug absorption is highly dependent on gastric emptying time and intestinal transit, TCAs can significantly alter the pharmacokinetics of co-administered drugs. For instance, delayed emptying may slow the absorption of drugs like paracetamol, or conversely, increase the total absorption of drugs that are poorly soluble by allowing them more time to dissolve in the gut. **Analysis of Incorrect Options:** * **Option A (Complexing):** This refers to chemical interactions (chelation) in the lumen, typical of drugs like **Cholestyramine** or **Antacids** (which bind to Tetracyclines/Fluoroquinolones), not TCAs. * **Option C (Altering gut flora):** This is a mechanism associated with **broad-spectrum antibiotics**, which can interfere with the enterohepatic circulation of drugs like oral contraceptives. * **Option D (Damaging gut mucosa):** This is characteristic of cytotoxic **chemotherapeutic agents** (e.g., Methotrexate) or chronic NSAID use, leading to malabsorption syndromes. **NEET-PG High-Yield Pearls:** * **Anticholinergic Toxidrome:** Remember the mnemonic "Blind as a bat, Mad as a hatter, Red as a beet, Hot as a hare, **Bowel and bladder lose their tone**." * **Other drugs causing decreased motility:** Opioids, Atropine, and Phenothiazines. * **Prokinetic agents:** Drugs like Metoclopramide *increase* motility and can speed up the absorption of other drugs.
Explanation: ### Explanation **Correct Option: B. Need to cross the cell membrane to produce the block** Local anesthetics (LAs) are weak bases. To be effective, the **unionized (lipid-soluble) form** must cross the neuronal lipid bilayer. Once inside the axoplasm, the molecule becomes **ionized (charged)** by picking up a hydrogen ion. It is this ionized form that binds to the specific receptor site on the **inner (cytoplasmic) aspect** of the voltage-gated sodium channel, leading to its blockade. **Analysis of Incorrect Options:** * **A. Greater potential to block a resting nerve:** This is incorrect. LAs exhibit **"use-dependent" or "state-dependent" blockade**. They have a higher affinity for channels in the **activated (open) or inactivated states** rather than the resting state. Therefore, a rapidly firing (stimulated) nerve is blocked faster than a resting one. * **C. Large myelinated fibers are blocked first:** This is incorrect. Generally, **smaller and myelinated fibers** are blocked more easily than larger, unmyelinated ones. The clinical sequence of blockade is typically: Pain → Temperature → Touch → Deep Pressure → Motor function. * **D. Cause consistent change of resting membrane potential:** This is incorrect. LAs do **not** alter the resting membrane potential. Instead, they decrease the rate of depolarization and the amplitude of the action potential, eventually preventing the threshold potential from being reached. **High-Yield NEET-PG Pearls:** * **Mechanism:** LAs are "membrane stabilizers" that block voltage-gated $Na^+$ channels. * **pH Effect:** In inflamed/acidic tissues (low pH), LAs exist mostly in the ionized form, which cannot cross the cell membrane, leading to **decreased efficacy**. * **Bicarbonate:** Adding sodium bicarbonate to LAs increases the unionized fraction, speeding up the **onset of action**. * **Sensitivity:** Type B and C fibers are blocked before Type A fibers.
Explanation: **Explanation:** **1. Why Clearance is the Correct Answer:** **Clearance (CL)** is defined as the theoretical volume of plasma from which a drug is completely removed per unit of time (e.g., mL/min). It represents the **efficiency of drug elimination**. [1] Mathematically, it is expressed as: * **Rate of elimination = Clearance × Plasma Concentration (C)** [1] In first-order kinetics (followed by most drugs), clearance remains constant, meaning the rate of elimination is directly proportional to the plasma concentration. [2] **2. Analysis of Incorrect Options:** * **Half-life (T1/2):** This is the time required for the plasma concentration of a drug to reduce by 50%. While related to elimination, it is a measure of *time*, not the *rate* of volume cleared. * **Biotransformation:** This refers to the chemical alteration of a drug (metabolism), usually in the liver. While it is a *process* that contributes to elimination, it is not the definition of the rate itself. * **Bioavailability:** This is the fraction of an administered dose of unchanged drug that reaches the systematic circulation. It relates to *absorption*, not elimination. **3. High-Yield NEET-PG Clinical Pearls:** * **Zero-order Kinetics:** A few drugs (e.g., **P**henytoin, **A**lcohol, **W**arfarin, **S**alicylates—Mnemonic: **PAWS**) have a constant *rate* of elimination regardless of concentration because their metabolic enzymes are saturated. [2] * **Steady State:** It takes approximately **4 to 5 half-lives** to reach a steady-state concentration. * **Maintenance Dose Calculation:** Clearance is the most important pharmacokinetic parameter used to calculate the maintenance dose of a drug. * **Formula to remember:** $T_{1/2} = \frac{0.693 \times Vd}{CL}$. This shows that half-life is inversely proportional to clearance.
Explanation: **Explanation:** **Concept of First-Pass Metabolism:** First-pass metabolism (presystemic elimination) refers to the extensive metabolism of a drug in the gut wall or liver before it reaches the systemic circulation. Drugs with high first-pass metabolism have low oral bioavailability, often necessitating higher oral doses or alternative routes of administration (e.g., sublingual, IV). **Analysis of Options:** * **Lignocaine (A):** It undergoes such extensive hepatic metabolism that its oral bioavailability is nearly zero. Therefore, it is never given orally for arrhythmias and is administered intravenously. * **Propranolol (B):** This is a classic example of a drug with high first-pass metabolism. The oral dose required to achieve therapeutic effects is significantly higher (e.g., 40–160 mg) compared to the intravenous dose (e.g., 1–3 mg). * **Salbutamol (C):** When taken orally, it undergoes significant metabolism in the gut wall by the enzyme sulfotransferase, leading to reduced bioavailability. Since all three drugs exhibit significant presystemic clearance, **Option D (All of the above)** is correct. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for High First-Pass Drugs:** "**L**ive **H**appily **P**rinting **M**oney **I**n **N**ew **T**exas" (**L**ignocaine, **H**ydrocortisone, **P**ropranolol/Pethidine, **M**orphine, **I**sosorbide dinitrate, **N**itroglycerin, **T**estosterone). * **Clinical Significance:** Patients with **liver cirrhosis** or portosystemic shunts may experience toxicity from these drugs due to decreased metabolism and increased systemic availability. * **Nitroglycerin:** Has the highest first-pass effect, which is why it is administered sublingually to bypass the liver.
Explanation: **Explanation:** The gluteal region is a common site for intramuscular (IM) injections, but it requires precise localization to avoid neurovascular injury. The correct site is the **Superolateral quadrant** of the buttock. **1. Why Superolateral is Correct:** The primary objective in choosing this quadrant is to avoid the **sciatic nerve**, the largest nerve in the body. By dividing the gluteal region into four quadrants, the superolateral area provides a thick mass of the gluteus medius and gluteus maximus muscles while remaining furthest from the sciatic nerve and major blood vessels (like the superior and inferior gluteal arteries). **2. Why Other Options are Incorrect:** * **Inferomedial & Superomedial:** These quadrants are avoided because the **sciatic nerve** typically courses through the deep layers of the medial and inferior aspects of the buttock. An injection here risks permanent nerve damage, leading to "foot drop" or sensory loss. * **Inferolateral:** This area is avoided due to the proximity of the sciatic nerve and the risk of injecting into the hip joint capsule or the bursa of the greater trochanter. **3. Clinical Pearls for NEET-PG:** * **Alternative Site:** The **Ventrogluteal site** (Gluteus medius) is increasingly preferred over the dorsogluteal site because it is free of major nerves and thick vessels. * **Nerve Injury:** The most common nerve injured by a misplaced IM injection in the buttock is the **Sciatic nerve**. * **Z-track Technique:** This is used during IM injections to prevent the leakage of irritating drugs (like Iron) into the subcutaneous tissue. * **Safe Landmark:** To find the superolateral quadrant, draw a line from the Posterior Superior Iliac Spine (PSIS) to the Greater Trochanter; the injection should be given lateral and superior to this line.
Explanation: **Explanation:** **Mechanism of Action (The Correct Answer):** Sildenafil is a selective inhibitor of **Phosphodiesterase-5 (PDE-5)**. In the corpus cavernosum of the penis, Nitric Oxide (NO) stimulates the enzyme guanylate cyclase, which increases levels of **cyclic Guanosine Monophosphate (cGMP)**. cGMP causes smooth muscle relaxation and inflow of blood. Normally, PDE-5 breaks down cGMP to terminate this action. By inhibiting PDE-5, Sildenafil prevents the degradation of cGMP, leading to prolonged vasodilation and improved erectile function. **Analysis of Incorrect Options:** * **Option A (PDE-3 Inhibition):** PDE-3 is primarily found in cardiac muscle and blood vessels. Drugs like **Milrinone** and **Amrinone** inhibit PDE-3, acting as inotropes and vasodilators used in heart failure. * **Option C (5-alpha Reductase Inhibition):** This enzyme converts testosterone to the more potent dihydrotestosterone (DHT). Inhibitors like **Finasteride** and **Dutasteride** are used to treat Benign Prostatic Hyperplasia (BPH) and male pattern baldness. * **Option D (Stimulation of androgen production):** Sildenafil does not affect the endocrine axis or testosterone levels; its effect is purely hemodynamic and local. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Sildenafil is the first-line treatment for Erectile Dysfunction and is also used in **Pulmonary Arterial Hypertension (PAH)** (under the brand name Revatio). * **Contraindication:** Never co-administer with **Nitrates** (e.g., Nitroglycerin) as it can lead to severe, life-threatening hypotension due to synergistic increases in cGMP. * **Side Effects:** Common side effects include headache, flushing, and **Cyanopsia** (blue-tinted vision) due to weak cross-inhibition of PDE-6 in the retina.
Absorption and Bioavailability
Practice Questions
Drug Distribution and Protein Binding
Practice Questions
Biotransformation and Metabolism Pathways
Practice Questions
Renal and Non-renal Excretion
Practice Questions
Compartment Models
Practice Questions
Dose-Response Relationships
Practice Questions
Drug Efficacy and Potency
Practice Questions
Drug Tolerance and Tachyphylaxis
Practice Questions
Population Pharmacokinetics
Practice Questions
Pharmacokinetic Variability
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free